title: Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.
abstract: We have designed and synthesized mixed backbone oligonucleotides (MBOs) containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments. Thermal melting studies of the phosphodiester MBOs (three 2'-5'linkages at each end) with the complementary 3'-5'-DNA and -RNA target strands suggest that 2'-5'-ribonucleoside incorporation into 3'-5'-oligodeoxyribonucleotides reduces binding to the target strands compared with an all 3'-5'-oligodeoxyribonucleotide of the same sequence and length. Increasing the number of 2'-5'linkages (from six to nine) further reduces binding to the DNA target strand more than the RNA target strand [Kandimalla,E.R. and Agrawal,S. (1996)Nucleic Acids Symp. Ser., 35, 125-126]. Phosphorothioate (PS) analogs of MBOs destabilize the duplex with the DNA target strand more than the duplex with the RNA target strand. Circular dichroism studies indicate that the duplexes of MBOs with the DNA and RNA target strands have spectral characteristics of both A- and B-type conformations. Compared with the control oligonucleotide, MBOs exhibit moderately higher stability against snake venom phosphodiesterase, S1 nuclease and in fetal calf serum. Although 2'-5'modification does not evoke RNase H activity, this modification does not effect the RNase H activation property of the 3'-5'-deoxyribonucleotide segment adjacent to the modification. In vitro studies with MBOs suggest that they have lesser effects on cell proliferation, clotting prolongation and hemolytic complement lysis than do control PS oligodeoxyribonucleotides. PS analogs of MBOs show HIV-1 inhibition comparable with that of a control PS oligodeoxyribonucleotide with all 3'-5'linkages. The current results suggest that a limited number of 2'-5'linkages could be used in conjunction with PS oligonucleotides to further modulate the properties of antisense oligonucleotides as therapeutic agents.
authors.affiliation: Hybridon Inc., One Innovation Drive, Worcester, MA 01605, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: Kandimalla
authors.forename: A
authors.initials: A
authors.lastname: Manning
authors.forename: Q
authors.initials: Q
authors.lastname: Zhao
authors.forename: D R
authors.initials: DR
authors.lastname: Shaw
authors.forename: R A
authors.initials: RA
authors.lastname: Byrn
authors.forename: V
authors.initials: V
authors.lastname: Sasisekharan
authors.forename: S
authors.initials: S
authors.lastname: Agrawal
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002942:Circular Dichroism; D003165:Complement System Proteins / Q000187:drug effects; D016373:DNA, Antisense / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D015750:Genes, gag / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects; D051379:Mice; D009690:Nucleic Acid Conformation; D009691:Nucleic Acid Denaturation; D009838:Oligodeoxyribonucleotides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D009843:Oligoribonucleotides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D010314:Partial Thromboplastin Time; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D016372:RNA, Antisense / Q000235:genetics; D016914:Ribonuclease H / Q000378:metabolism; D015719:Single-Strand Specific DNA and RNA Endonucleases / Q000378:metabolism; D013053:Spectrophotometry; D013154:Spleen / Q000378:metabolism
chemical_list: D016373:DNA, Antisense; D009838:Oligodeoxyribonucleotides; D009843:Oligoribonucleotides; D016372:RNA, Antisense; D003165:Complement System Proteins; D016914:Ribonuclease H; D015719:Single-Strand Specific DNA and RNA Endonucleases; D010727:Phosphoric Diester Hydrolases; D043264:Phosphodiesterase I; C470790:phosphodiesterase I, snake venom